"Specifically, we now see price deflation as eroding sales of the Teva products by 5% annually to fiscal 2021, versus our prior assumption that pricing would rebound past this year. As a result, we lower our fair value estimate to AUD 1.70 per share, from AUD 2.00 previously, but we still view the shares as undervalued at current levels."
http://news.morningstar.com/articlenet/article.aspx?id=813068
Bell Potter downgrades target to $1.63, page-5
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.81 |
Change
-0.100(2.56%) |
Mkt cap ! $324.1M | |||
| Open | High | Low | Value | Volume |
| $3.96 | $4.01 | $3.78 | $706.7K | 182.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2573 | $3.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.83 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| MYX (ASX) Chart |